Skip to main content

Advertisement

SpringerLink
Log in

Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Autologous peripheral blood stem cell transplantation is the therapy of choice for the treatment of multiple myeloma (MM) patients younger than 70 years old. Between August 1993 and November 2004, 54 patients with MM were autografted after conditioning with high-dose oral melphalan 140 mg/m2 in combination with etoposide and carmustine (28 patients) or with high-dose melphalan 200 mg/m2 I.V. (26 patients). The oral and IV melphalan groups were comparable. There were no significant differences in disease-free survival (DFS) and overall survival (OS) between the groups; however, in patients transplanted in remission, OS and DFS were better in the I.V. melphalan group. Four good-prognostic factors were identified: interval between diagnosis and transplant <18 months, number of prior chemotherapy lines ≤2, remission status (complete or partial), and the use of I.V. melphalan. In conclusion, I.V. melphalan is the therapy of choice for conditioning patients with MM who are in remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE (1996) High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 17:335–340

    PubMed  CAS  Google Scholar 

  2. Alegre A, Lamana M, Arranz R, Fernandez-Villalta MJ, Tomas JF, Figuera A et al (1995) Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 91:380–386

    PubMed  CAS  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91–97

    Article  PubMed  CAS  Google Scholar 

  4. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J et al (1998) Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 21:1101–1107

    Article  PubMed  CAS  Google Scholar 

  5. Bergsagel DE (1989) Melphalan/prednisone vs drug combinations for plasma cell myeloma. Eur J Haematol 43(Suppl 51):117–123

    Google Scholar 

  6. Boccadoro M, Marmont F, Tribalto M (1991) VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone in the treatment of multiple myeloma even in high risk patients. J Clin Oncol 9:444–448

    PubMed  CAS  Google Scholar 

  7. Bosanquet AG, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18:355–362

    Article  PubMed  CAS  Google Scholar 

  8. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883

    Article  PubMed  CAS  Google Scholar 

  9. Fassas A, Shaughnessy J, Barlogie B (2005) Cure of myeloma: hype or reality? Bone Marrow Transplant 35:215–224

    Article  PubMed  CAS  Google Scholar 

  10. Gibson J, Ho PJ, Joshua D (2004) Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogeneic transplantation. Transplant Proc 8:2501–2503

    Article  Google Scholar 

  11. Vela-Ojeda J, Sanchez-Cortes E, Ayala-Sanchez M, Garcia-Chavez J, García-Ruiz Esparza MA, Tripp-Villanueva F et al (1998) Treatment of relapse and refractory multiple myeloma (MM) with intermediate doses of oral melphalan, dexamethasone and GM-CSF (M-80) versus VAD chemotherapy. Blood 92(10) Suppl 1, 284b, abstract # 4225

  12. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD (1988) Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 71:723–727

    PubMed  CAS  Google Scholar 

  13. Lahuerta JJ, Grande C, Blade J (2002) Myeloablative treatments for multiple myeloma: update of comparative study of different regimens used in patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leuk Lymph 43:67–74

    Article  Google Scholar 

  14. Moreau P, Facon T, Attal M (2002) Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 99:731–735

    Article  PubMed  CAS  Google Scholar 

  15. Reece PA, Kostasek D, Morris RG (1986) The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol 49:1318–1321

    Google Scholar 

  16. Ruiz-Argüelles A (1992) Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 50:735–743

    Google Scholar 

  17. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Aguilar-Romero L (2004) Multiple myeloma in México: a single institution, twenty-year experience. Arch Med Res 35:163–167

    Article  PubMed  Google Scholar 

  18. Samuels BL, Bitran JD (1995) High-dose intravenous melphalan: a review. J Clin Oncol 13:1786–1799

    PubMed  CAS  Google Scholar 

  19. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD (1988) The systemic administration of intravenous melphalan. J Clin Oncol 6:1768–1782

    PubMed  CAS  Google Scholar 

  20. Tricot G, Alberts DS, Johnson C (1996) Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 2:947–952

    PubMed  CAS  Google Scholar 

  21. Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chavez J, Tripp-Villanueva F et al (2002) Intermediate doses of melphalan and dexamethasone are better than VAD chemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 81:262–267

    Google Scholar 

  22. Wildiers H, Highley S, De Bruijn EA, Van Oosterom AT (2003) Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42:1213–1242

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was approved by the ethical committees of the participant hospitals and is in accordance with the Helsinki Declaration of 1975 and complies with the current health and research laws of México.

Author information

Authors and Affiliations

  1. UMAE Hospital de Especialidades Centro Médico La Raza, IMSS, Apartado Postal 14-878 CP, 07001, México, D.F., México

    J. Vela-Ojeda, M. A. García-Ruiz-Esparza & Y. Padilla-González

  2. Hospital Universitario de Nuevo León, Monterrey Nuevo León, México

    D. Gómez-Almaguer, C. H. Gutiérrez-Aguirre & G. J. Ruiz-Delgado

  3. Centro de Hematología y Medicina Interna de Puebla, Puebla, Puebla, México

    D. Gómez-Rangel, A. Morales-Toquero & G. J. Ruiz-Argüelles

  4. UMAE Hospital de Especialidades Centro Médico de Occidente, IMSS, Guadalajara Jalisco, México

    J. L. Delgado-Lamas

Authors
  1. J. Vela-Ojeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. García-Ruiz-Esparza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Padilla-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Gómez-Almaguer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. H. Gutiérrez-Aguirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Gómez-Rangel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Morales-Toquero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. J. Ruiz-Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. L. Delgado-Lamas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. J. Ruiz-Argüelles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Vela-Ojeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vela-Ojeda, J., García-Ruiz-Esparza, M.A., Padilla-González, Y. et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Ann Hematol 86, 277–282 (2007). https://doi.org/10.1007/s00277-006-0235-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-006-0235-9

Keywords

Search

Navigation